![]() |
市場調查報告書
商品編碼
1372019
到 2030 年心臟去顫器市場預測:按類型、患者類型、最終用戶和地區分類的全球分析Defibrillator Market Forecasts to 2030 - Global Analysis By Type (Implantable Cardioverter Defibrillators and External Defibrillators), Patient Type (Adult and Pediatric), End User and By Geography. |
根據 Stratistics MRC 的數據,2023 年全球心臟去顫器市場規模為 154.9 億美元,預計在預測期內將以 8.6% 的年複合成長率成長,到 2030 年達到 275 億美元。
心臟去顫器是醫療設備,旨在向心臟提供電擊以恢復正常心率,特別是在發生危及生命的心室心搏過速)的情況下。這些異常的心律會導致心臟顫抖或快速跳動,導致心臟麻痹。心臟去顫器對於立即治療至關重要,它可以透過電擊幫助心臟恢復正常節律並改善全身的血液循環。心臟去顫器廣泛應用於醫院、心臟監護室、急診室和手術室,以管理心律不整並快速回應心臟緊急情況。
根據冠狀動脈疾病基金會 2022 年發布的報告,美國年度報告約 356,000 例院外心臟麻痹(OHCA)。
世界上很大一部分人口受到冠狀動脈疾病和心臟麻痹等心血管疾病的影響。冠狀動脈疾病更可能導致心律不整性心因性猝死。肥胖、高血壓、血脂異常症和糖尿病等生活型態因素會增加多種心血管疾病的風險。此外,導致CVD患病增加的一個主要要素是世界老年人口的增加。由於心臟結構和功能逐漸惡化和複雜化,老齡化使室心室心律不整的發生急劇增加,導致心臟心律不整的患病增加。所有這些要素預計將推動對心臟去顫器的需求,這些設備可以在心臟緊急情況下提供及時介入。
心臟去顫器可能非常昂貴,特別是對於具有增強功能和性能的高級型號。這種高成本給資源有限的醫療保健提供者、設施和社區帶來了挑戰,限制了他們投資救生設備的能力。此外,負擔能力阻礙了普及和可近性,阻礙了在公共場所和醫療機構安裝心臟去顫器的配合措施。解決成本障礙對於確保更廣泛的可用性和利用至關重要,特別是在服務不足的社區和資源有限的醫療保健系統中。
隨著世界人口老化,心臟疾病的發病率和心臟麻痹(SCA)的風險不斷增加。擁有心臟去顫器對老年人來說最重要,因為高齡化通常與多種心臟病有關。在心臟緊急情況下,心臟去顫器對於心臟復甦至關重要,可以大大增加生存機會。由於老年人更容易患心臟病,因此老年護理機構、療養院、福利設施和家庭護理中越來越需要心臟去顫器。此外,由於心臟去顫器技術的進步,包括專門為滿足老年人口的需求而製造的設備,心臟去顫器變得越來越普及和廣泛使用。製造商正在投資研究開發適合年齡的心臟去顫器解決方案,以滿足老年人的獨特需求,並提供符合世界人口向高齡化社會轉變的有前景的解決方案,創造市場機會。
科技顛覆和創新對心臟去顫器市場構成重大威脅。醫療技術的快速進步,包括小型化、人工智慧、連接性和先進材料,可能會使當前的心臟去顫器型號過時或競爭下降。穿戴式和連接技術可以徹底改變心臟監測和緊急應變,減少對傳統心臟去顫器的需求。此外,再生醫學和生物工程的突破可能透過專注於心臟組織的再生和修復來提供心臟去顫器的替代品。如果未能跟上這些技術創新的步伐,可能會導致市場佔有率下降並減少對傳統心臟去顫器的需求。
COVID-19大流行預計將對全球心臟去顫器市場的成長產生負面影響。疫情損害了醫院,尤其是小型醫院的購買力,導致供應交易和程序取消和推遲,影響了所有主要心臟去顫器市場競爭的整體收入。世界各地的醫療保健系統必須處理的主要問題是後勤問題、疾病管理、優先照顧患有合併症和既有疾病的患者,以及公眾和醫院一線工作人員的需求。進一步保護人們免受COVID-19 的侵害。商品和服務的交付速度也受到各國最近實施的包裝法規和封鎖程序的影響。心臟去顫器市場製造和供應鏈受到這些問題的負面影響。
據估計,植入式心臟整流去顫器市場佔最大佔有率。植入式心臟整流去顫器(ICD) 是一種植入式醫療設備,旨在監測和管理心律不整,特別是心室心律不整。由於心臟疾病患病的增加和人口高齡化的加劇,ICD 市場正在經歷顯著成長。 ICD 可解決一級預防(對於有發生危及生命的心律不整風險的人)和二級預防(對於已經經歷過心臟事件的人)的問題。此外,技術的進步帶來了更小、更複雜的 ICD,具有遠端監控和針對心搏過緩患者的整合起搏器等功能。此外,ICD 在治療心律不整、改善患者生活品質和降低死亡率方面繼續發揮關鍵作用,使其成為心臟去顫器市場的關鍵結構要素。因此,心臟去顫器市場預計將出現良好的成長。
預計醫院、診所和心臟中心領域將在預測期內出現良好成長。醫院、診所和心臟中心對於心臟去顫器的採用、使用和分發至關重要。這些是初級照護端,心臟去顫器對於治療心臟麻痹(SCA) 和其他危及生命的心律不整至關重要。在醫院和心臟中心,心臟去顫器是急診室、重症監護室、心導管實驗室和手術室的重要組成部分。此外,許多診所和公共衛生保健中心都備有自動體外心臟去顫器(AED),可用於應對機構內或週邊地區發生的心臟事件。在這些情況下,去心房顫動。確保醫院、診所和心臟中心心臟去顫器的可用性和可及性對於挽救生命和改善心臟治療結果仍然至關重要。因此,它正在支持該領域的成長。
由於美國和加拿大主要企業的舉措、有利的法規以及技術先進的醫療設施,北美在預測期內佔據了最大的市場佔有率。 2022 年,北美地區的收益佔有率最大,超過 42.2%。例如,波士頓科學公司表示,到年終,該公司已在全球部署了約 33,000 台 CRT-D 系列的 Autogen、Incepta、Resonate、Cognis 和 Dynagen 設備。其中,光在美國就有 16,500 個註冊,普及強勁。由於該地區醫療設施高度發展以及研發活動支出不斷增加,美國在心臟去顫器市場佔據主導地位。此外,體外心臟去顫器不僅擴大安裝在醫院,而且擴大安裝在學校、酒店、道路和火車站等公共場所,以防止心臟麻痹。 ,這是心臟去顫器佔有率高的一個主要要素北美市場。
由於患者人數增加、醫療基礎設施擴大以及冠心病發病率高,預計亞太地區在預測期內將出現盈利成長。普及心臟去顫器的高普及率和日本的支持政策正在支持區域擴張。此外,隨著該地區患者群體的擴大以及公眾對公共心臟去顫器認知度的提高,隨著基礎設施支出和心臟去顫器普及的提高,該地區的市場開拓將會加速。此外,像日本這樣的國家,由於存在著專注於拓展其他地區市場的大公司,心臟去顫器的普及很高,這也有可能擴大全球心臟去顫器市場。
According to Stratistics MRC, the Global Defibrillator Market is accounted for $15.49 billion in 2023 and is expected to reach $27.50 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Defibrillators are medical devices designed to deliver an electric shock to the heart in order to restore a normal heartbeat, especially during life-threatening cardiac arrhythmias like ventricular fibrillation or ventricular tachycardia. These abnormal heart rhythms can cause the heart to quiver or beat too fast, leading to cardiac arrest. Defibrillators are vital in providing immediate treatment by administering an electric shock, which helps the heart re-establish a regular rhythm and improves blood circulation throughout the body. Defibrillators are extensively used in hospitals, cardiac care units, emergency rooms, and operating rooms to manage cardiac arrhythmias and to provide rapid response in case of cardiac emergencies.
According to the report published by the Coronary Artery Disease Foundation in 2022, around 356,000 out-of-hospital cardiac arrests (OHCA) are reported annually in the US.
A significant portion of the global population are impacted by cardiovascular diseases such coronary artery disease and cardiac arrest. Arrhythmic sudden cardiac death is more likely as a result of coronary artery disease. The risk of acquiring numerous cardiovascular illnesses is mostly increased by lifestyle conditions such obesity, hypertension, dyslipidemia, and diabetes. In addition, a significant contributor in the increased prevalence of CVD is the growing worldwide elderly population. Due to the gradual deterioration and increase in complexity in the structure and function of the heart, ageing is connected with an exponential rise in the development of ventricular arrhythmias, resulting in an increase in the prevalence of arrhythmias in the heart. All these factors are anticipated to propel the demand for defibrillators to provide timely intervention with these devices during cardiac emergencies.
Defibrillator devices can be prohibitively expensive, especially advanced models with enhanced features and capabilities. This high cost poses a challenge for healthcare providers, facilities, and regions with constrained financial resources, limiting their ability to invest in these life-saving devices. Additionally, affordability concerns hinder widespread adoption and accessibility, hampering efforts to equip public spaces and healthcare institutions with defibrillators. Addressing cost barriers is crucial to ensuring broader availability and utilisation, particularly in underserved communities and resource-constrained healthcare systems.
The incidence of cardiac diseases and the risk of sudden cardiac arrest (SCA) rise along with an increase in the number of elderly people worldwide. Defibrillator adoption is of the utmost importance for the senior population because ageing is typically accompanied by a variety of cardiac issues. In cardiac emergencies, defibrillators are essential for reviving the heart, greatly increasing the likelihood of survival. Defibrillators are becoming more necessary in geriatric care settings, nursing homes, assisted living facilities, and at-home care since the elderly are more prone to cardiac episodes. Moreover, defibrillators are becoming more popular and widely used due to developments in defibrillator technology, such as devices made specifically to meet the demands of the senior population. Manufacturers are investing in research to develop age-appropriate defibrillator solutions to meet the distinct requirements of older individuals, creating a promising market opportunity that aligns with the global demographic shift towards an ageing society.
Technological disruption and innovation pose a significant threat to the defibrillator market. The rapid evolution of medical technology, encompassing miniaturization, artificial intelligence, connectivity, and advanced materials, has the potential to render current defibrillator models obsolete or less competitive. Wearable and connected technologies might revolutionize cardiac monitoring and emergency response, potentially reducing the need for traditional defibrillators. Furthermore, breakthroughs in regenerative medicine and bioengineering could offer alternatives to defibrillators by focusing on cardiac tissue regeneration and repair. Failure to keep pace with these innovations could result in declining market share and diminished demand for traditional defibrillators.
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global defibrillator market. The pandemic damaged hospitals' purchasing power, especially minor hospitals, which led to cancelled or postponed supply deals and procedures, which had an effect on the overall income of all the major defibrillator market competitors. The main issues that healthcare systems around the world had to deal with were logistical issues, sickness management, giving priority to patients with comorbidities and pre-existing problems, and further protecting the general public and hospital frontline workers from COVID-19. The speed of delivery of goods and services was also impacted by more recent packaging restrictions and country-imposed lockdown processes. The manufacturing and supply chain for the defibrillator market are adversely affected by each of these issues.
The Implantable Cardioverter Defibrillators segment is estimated to hold the largest share. Implantable Cardioverter Defibrillators (ICDs) are implantable medical devices designed to monitor and manage irregular heart rhythms, specifically ventricular arrhythmias. The ICD market has experienced significant growth due to the increasing prevalence of cardiac conditions and a growing ageing population. It caters to both primary prevention (for individuals at risk of developing life-threatening arrhythmias) and secondary prevention (for those who have already experienced cardiac events). Moreover, due to the technological advancements it has smaller and more sophisticated ICDs, with features like remote monitoring and integrated pacemakers for bradycardia patients. Additionally, ICDs continue to play a critical role in managing cardiac arrhythmias, improving patient quality of life, and reducing mortality rates, making them a key component of the defibrillator market. Therefore, there is lucrative growth for the defibrillator market.
The Hospitals, Clinics and Cardiac Centres segment is anticipated to have lucrative growth during the forecast period. Hospitals, clinics, and cardiac centres are crucial in the adoption, utilisation, and distribution of defibrillators. They serve as primary points of care where defibrillators are essential in treating sudden cardiac arrest (SCA) and other life-threatening arrhythmias. In hospitals and cardiac centres, defibrillators are integral components of emergency rooms, critical care units, cardiac catheterization labs, and operating rooms. Additionally, many clinics and public healthcare centres have AEDs readily accessible to respond to cardiac events in their facilities or surrounding areas. Proper training and education regarding defibrillator usage are essential in these settings to enhance the efficacy and impact of defibrillation efforts. Ensuring the availability and accessibility of defibrillators in hospitals, clinics, and cardiac centres remains paramount to saving lives and improving cardiac care outcomes. Thus, it is propelling segment growth.
North America commanded the largest market share during the extrapolated period owing to initiatives by key players, favourable regulations, and technologically advanced healthcare facilities in the U.S. and Canada. North America held the largest revenue share of more than 42.2% in 2022. For instance, Boston Scientific stated that by the end of 2020, it had deployed about 33,000 Autogen, Incepta, Resonate, Cognis, and Dynagen devices from its CRT-Ds line globally. A strong adoption rate can be seen in the fact that 16,500 of these were registered in the U.S. alone. It dominates the defibrillator market because of the prevailing sophisticated level of healthcare facilities and rising expenditure for research and development activities in this region. Additionally, growing installations of external defibrillators in hospitals as well as in public places such as schools, hotels, streets, railway stations, and others with the aim of preventing fatalities from sudden cardiac arrest is prominently responsible for holding a higher defibrillator market share in North America.
Asia-Pacific region is expected to witness profitable growth over the projection period, due to an increasing patient population, an expanding healthcare infrastructure, and the frequency of coronary diseases. A high defibrillator penetration rate and supportive policies in Japan are boosting regional expansion. Additionally, as a result of the region's expanding patient base and growing public awareness of public-access defibrillators, the market in this area will experience faster development as infrastructure spending and defibrillator penetration rise. Moreover, countries such as Japan have a high penetration of defibrillators due to the presence of giant companies that are focused on expanding the market in other geographies, which is also likely to augment the global defibrillator market.
Some of the key players in the Defibrillator Market include: Abbott Laboratories, Inc., Medtronic, MicroPort Scientific Corporation, Boston Scientific Corporation, ZOLL Medical Corporation, Schiller AG, Nihon Kohden Corporation, StrykerCorporation, PhilipsHealthcare, CardiacScienceCorporation, LivaNovaPLC, Asahi Kasei Corporation, Biotronik, CU Medical System Inc., Koninklijke Philips N.V., Metrax GmbH, Progetti srl, Defibtech LLC, HeartSine Technologies LLC and Mindray Medical International Limited.
In December 2022, Abbott Launches Navitor™, Its Latest-Generation Transcatheter Aortic Valve Implantation (Tavi) System To Treat Aortic Stenosis In India. Global healthcare company, Abbott announced that it has launched its latest-generation transcatheter aortic valve implantation (TAVI) system, NavitorTM, making the minimally invasive device available for people in India with severe aortic stenosis who are at high or extreme surgical risk.
In September 2022, Abbott Launches New Ensure With Hmb To Help Protect And Strengthen Indian Adults' Muscles. The new Ensure with HMB and 32 nutrients is a clinically-tested, science-based nutritional supplement specially designed to protect and strengthen muscles.
In July 2022, Abbott Launches Grow Right 2.0 Highlighting The Right M-E-A-N-S To Help Parents Foster Holistic Growth In Children. Abbott has launched its Grow Right 2.0 charter introducing M-E-A-N-S guidelines for good practices in Measuring growth, Eating, Activity, Nurturing and Sleep. Abbott's Grow Right 2.0 Charter can help parents address concerns with expert-backed guidelines to help encourage healthy habits in children